A combined intrapleural administration of dornase alfa and tissue plasminogen activator is safe in children with empyema – A pilot study. Issue 3 (4th May 2021)

• Record Type: Journal Article
• Authors: Slaats, Monique A.; De Dooy, Jozef; Van Hoorenbeeck, Kim; Van Schil, Paul E. Y.; Verhulst, Stijn L.; Hendriks, Jeroen M. H.
• Is Part Of: Acta chirurgica belgica. Volume 121:Issue 3(2021)
• Page Start: 184
• Page End: 188
• Publication Date: 2021-05-04
• Subjects: Pediatrics -- empyema -- treatment; Surgery -- Periodicals; General Surgery; Chirurgie -- Périodiques; Surgery; Chirurgie (geneeskunde); Periodicals; Periodicals; 617.005
• DOI: 10.1080/00015458.2019.1696516
• Languages: English
• ISSNs: 0001-5458

Abstract

Abstract: Objective: There is still no consensus regarding the treatment of empyema in children. Intrapleural combination of tissue plasminogen activator and dornase alfa is a promising treatment for empyema in adults. The aim of this pilot study was to determine whether this combination is safe and successful in pediatric empyema. Methods: Previous well children diagnosed with empyema as classified by the British Thoracic Society. After chest tube insertion, intrapleurally dornase alfa 2.5 mg for 2 days and tissue plasminogen activator 0.15 mg/kg for 3 days was given after which the chest tube was clamped for 4 h. Primary outcome was safety. Results: Ten consecutive children were included (4 boys, aged 3.2 (1.3–15.0) years old). No serious adverse events were seen. One child developed urticaria but additional intervention or cessation of the trial was not needed. There was no bleeding or mortality and no additional procedures were performed. The median hospital stay after intervention was 7.5 days. Conclusions: The intrapleural treatment of dornase alfa and tissue plasminogen activator as treatment of empyema was safe in ten children with empyema. If confirmed in further studies, this combination of intrapleural therapy may improve the management of pediatric empyema.